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Prostate cancer has become a major public health issue. The
application of screening technology incorporating digital rectal
examination, measurement of PSA and use of transrectal ultra-
sonography has identified a huge reservoir of previously
undetected cases. For a short time, this gave the semblance of an
‘epidemic’, although it soon became clear that this was not the case
and only reflected the reservoir effect. Despite the absence of
definitive, structured proof of the benefit of screening for prostate
cancer, politicians, health authorities, advocacy groups and
innocent bystanders have weighed into the debate on the benefits
of screening and early intervention (Raghavan, 1997). This has
focused attention on all aspects of prostate cancer care, including
the utility of cytotoxic chemotherapy (Beer and Raghavan, 2000).
The Minireview by Canil and Tannock has accurately sum-
marised what we know about the benefits and drawbacks of
chemotherapy for prostate cancer (Canil and Tannock, 2004). For
locally advanced disease, several provocative phase I–II trials have
suggested that there may be a biological effect from the early use of
cytotoxics, either prior to definitive treatment or as classical
adjuvant therapy. In truth, a larger biological impact on the
outcome of treatment for locally advanced (stage C) disease is seen
from hormonal therapy, especially when delivered over a
protracted period of 1–3 years (Bolla et al, 2002). An important
randomised trial (Southwest Oncology Group (SWOG) 9921) is
currently assessing the role of adjuvant hormonal therapy plus
mitoxantrone, compared to adjuvant hormones alone, for locally
extensive prostate cancer after radical prostatectomy. As Canil and
Tannock note, there is no role for ‘routine’ neoadjuvant or
adjuvant cytotoxics for locally advanced prostate cancer unless in a
structured clinical trial.
For metastatic disease, at the time that the review was written,
there was no definitive published proof of a survival benefit from
chemotherapy. The authors noted that chemotherapy could
improve quality of life for patients with metastatic hormone
refractory disease. In the study reported by Tannock et al (1996),
there was a dramatic improvement in the quality of life and cost of
treatment (Bloomfield et al, 1998), but no obvious survival benefit
gained from early institution of mitoxantrone chemotherapy.
Importantly, however, this study allowed crossover, and patients
treated only with prednisone initially were allowed to receive
subsequent chemotherapy upon relapse, thus potentially vitiating
any survival benefit. In my view, the trial reported by Tannock et al
suggested that it may be safe to use conservative means initially
prior to implementing cytotoxic chemotherapy; that is, there was
no obvious survival benefit from early chemotherapy compared to
elective chemotherapy after first subsequent relapse.
Since the submission of this Minireview, the results of two trials
mentioned by the authors have entered the public domain, having
been presented at the Annual Scientific Meeting of the American
Society of Clinical Oncology. Eisenberger et al (2004) presented the
results of a study sponsored by Aventis Pharmaceuticals, TAX 327,
which compared a schedule of 3-weekly taxotere vs weekly taxotere
vs 3-weekly mitoxantrone, each agent being administered with
continuous oral prednisone. For the first time, this trial showed a
statistically significant survival benefit achieved from 3-weekly
taxotere compared to 3-weekly mitoxantrone. Consistent findings
were identified with respect to symptomatic improvement, PSA
reduction and objective tumour response. Of importance, the
difference in the median survival was only 2 months, and there was
no dramatic difference in outcomes beyond 2 years. Similarly,
Petrylak et al, reporting results of a North American Intergroup
trial led by the Southwest Oncology Group (trial SWOG 9921),
demonstrated a statistically significant difference between mitox-
antrone–prednisone and taxotere–estramustine. Once again, the
difference in the median survival was only 2 months and there was
no obvious long-term impact. Nonetheless, these studies do show a
clear role for cytotoxic chemotherapy that includes improvement
in survival, objective and subjective tumour response and quality
of life.
One of the complex issues that remain unresolved is our
inability to measure quality of life optimally for patients with
prostate cancer. The studies cited above (Tannock et al, 1996;
Eisenberger et al, 2004; Petrylak et al, 2004) all demonstrate
surprising discordance between response, measured quality of life,
assessment of pain on structured quantification scales and long-
term outcome. This may be due to the impact of toxicity; for
example, it is clear that taxotere causes more side effects than does
mitoxantrone, and this may contribute to this discrepancy.
Alternatively, it may reflect the oft underestimated impact of
castration, with a range of physical, emotional and behavioural
costs.
What is quite clear is that we are making slow progress in
evolving treatment of prostate cancerybut it IS progress. Slowly
the median survival is improving, notwithstanding the impact of
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toxicity of treatment. At present, it appears that taxotere has
become a new standard initial chemotherapy for metastatic
prostate cancer, but it is clearly an imperfect standard that does
not merit the loud huzzahs that will clearly follow. Mitoxantrone
also remains a useful agent, and it is really not clear whether a
huge gain is achieved by the use of one agent first. In fact, it may
well be that there is still a place for the vanishing paradigm of old-
fashioned clinical skill and judgment. For example, the patient
with multiple medical issues and slowly evolving, symptomatic
disease may well be treated more successfully by a gentler
induction regimen.
The final issue is to understand why progress in prostate cancer
has been so much slower than in cancer of the breast. It has been
postulated that prostate cancer is more heterogeneous and innately
drug resistant, that it afflicts older and less robust patients, or that
the impact of neuroendocrine cells confounds the assessment of
outcome. To me, the answer is relatively simple: failure of many
physicians to encourage their patients to enter structured clinical
trials that reflect sensible clinical questions and well-defined end
points or failure of patients to accept the concept that uncertainties
in medicine are often best resolved through clinical trials rather
than via rash empiricism.
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